Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
For this pilot MRP study, we will additionally apply the following Criteria:
Consents to follow-up contact
US residents
Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
No metallic artifacts covering the pancreas on prior MRCP
Scheduled for endoscopic ultrasound
No new contraindications for MRI (e.g. new MR unsafe device)
No history of claustrophobia or use of anxiolytic on prior MRI
No history of abdominal surgery that may affect interpretation of either EUS or MR
No medical conditions that confers increased and/or unacceptable risk for anesthesia
We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.
Documentation of Disease
o No pathologic confirmation of disease is necessary
Definition of Disease N/A
Required Organ Function N/A
You may not be if
\-
Clareo Health | A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
